Mentions
Extended reach
Total likes
Video views
AI synopsis
The analysis reveals strong support and high interest in the publication, with posts citing concrete research outcomes like reduced binge-drinking days (IRR=0.74) and emphasizing the potential practice-changing nature of the study, using words like 'really nice' and 'significantly'. The tone and references to clinical implications demonstrate deep engagement and a recognition of the research's meaningful impact.
Most posts support the findings and effectiveness of targeted oral naltrexone for alcohol use disorder among sexual and gender minority men.
Discussions show high engagement with the topic, with multiple posts calling the article 'really nice' or emphasizing its potential to change practice.
Several discuss specific results, such as reductions in binge-drinking days and craving, indicating deep engagement.
The posts highlight the significant implications for clinical practice, policy, and future research, reflecting high perceived impact.
I love discussing pharmacology because it’s freaking cool. The art of medicine: killing too many birds with one stone: bupropion-naltrexone stimulates POMC and blocks auto-inhibitory feedback on POMC leading to lower energy homeostasis (weight https://t.co/GMAiMhaP3z
Really nice paper, on naltrexone as needed (pre-binge or craving) for mildish alcohol use disorder https://t.co/JZO32uh7Cg
Dr. Glenn-Milo Santos and @UCSF @SF_DPH colleagues report that among sexual and gender minority individuals with mild - moderate alcohol use disorder, oral naltrexone treatment targeting periods of alcohol craving significantly reduced heavy drinking. https://t.co/Skc6FrGBYh https://t.co/U4mEVuFa7Y
We love the Episode 20 article about targeted naltrexone in sexual and gender minority men. It has changed our practices. Would it change yours? #alcoholusedisorder #naltrexone #bingedrinking #AMJC #addictionmedicine #MedEd https://t.co/BS88wQPImL
HPTN Scholar Dr. Glenn-Milo Santos and @UCSF @SF_DPH colleagues report that among sexual and gender minority individuals with mild-moderate alcohol use disorder, oral naltrexone treatment significantly reduced heavy drinking. https://t.co/bAA6PKf54Q
Naltrexone RCT 50mg for avg. 2.5 days/wk --> At 6 months , naltrexone ⬇️ no. of drinks/month (IRR=0.69, 95% CI=0.50, 0.97), no. of binge-drinking days (IRR=0.67, 95% CI=0.47, 0.95), and any binge drinking in the past week (IRR=0.79, 95% CI=0.63, 0.99). https://t.co/4IRoMah5IK
This video provides quick summaries of the last 10 articles related to substance use, including wine consumption, opioid use in rural communities, cognitive effects of prescription opioids in older adults, early life…
This video summarizes the key findings from several recent studies, including a cohort analysis comparing buprenorphine and methadone for treating opioid use disorder during pregnancy. The results highlight the benefits…
20. Santos GM, et al. Targeted Oral Naltrexone for Mild to Moderate Alcohol Use Disorder Among Sexual and Gender Minority Men: A Randomized Trial. Am J Psychiatry. 2022 Dec 1;179(12):915-926. Epub 2022 Oct 26. https://t.co/BS88wQPaxd
RT @AddictionMedJC: We love the Episode 20 article about targeted naltrexone in sexual and gender minority men. It has changed our practice…
We love the Episode 20 article about targeted naltrexone in sexual and gender minority men. It has changed our practices. Would it change yours? #alcoholusedisorder #naltrexone #bingedrinking #AMJC #addictionmedicine #MedEd https://t.co/BS88wQPImL
Episode 20 citation: Santos GM, Et al. Targeted Oral Naltrexone for Mild to Moderate Alcohol Use Disorder Among Sexual and Gender Minority Men: A Randomized Trial. Am J Psychiatry. 2022 Dec 1;179(12):915-926. Epub 2022 Oct 26. https://t.co/BS88wQPImL
The next Addiction Med Journal Club podcast is coming up. Get the article from AmJPsych about #naltrexone and binge-drinking. “Targeted Oral Naltrexone for Mild to Moderate Alcohol Use Disorder Among Sexual and Gender Minority Men.” https://t.co/BS88wQPaxd
RT @sdpnayak: Really nice paper, on naltrexone as needed (pre-binge or craving) for mildish alcohol use disorder https://t.co/JZO32uh7Cg
Really nice paper, on naltrexone as needed (pre-binge or craving) for mildish alcohol use disorder https://t.co/JZO32uh7Cg
Dr. Glenn-Milo Santos, an Early Independence awardee from our #NIHHighRisk High-Reward Research Program, and @UCSF researchers reports pill that significantly curbs #BingeDrinking by reducing #AlcoholCravings for mild to moderate alcohol use disorder. https://t.co/eIAbwTW7wM https://t.co/wPmdJmcIiU
Naltrexone RCT 50mg for avg. 2.5 days/wk --> At 6 months , naltrexone ⬇️ no. of drinks/month (IRR=0.69, 95% CI=0.50, 0.97), no. of binge-drinking days (IRR=0.67, 95% CI=0.47, 0.95), and any binge drinking in the past week (IRR=0.79, 95% CI=0.63, 0.99). https://t.co/4IRoMah5IK
I love discussing pharmacology because it’s freaking cool. The art of medicine: killing too many birds with one stone: bupropion-naltrexone stimulates POMC and blocks auto-inhibitory feedback on POMC leading to lower energy homeostasis (weight https://t.co/GMAiMhaP3z
I love discussing pharmacology because it’s freaking cool. The art of medicine: killing too many birds with one stone: bupropion-naltrexone blocks auto-inhibitory feedback on POMC leading to lower energy homeostasis (weight reduction). Also, it helps https://t.co/GMAiMhaP3z
Targeted Oral Naltrexone for Mild to Moderate Alcohol Use Disorder Among Sexual and Gender Minority Men: A Randomized Trial https://t.co/zrepl7QdKq
RT @HIVptn: HPTN Scholar Dr. Glenn-Milo Santos and @UCSF @SF_DPH colleagues report that among sexual and gender minority individuals with m…
HPTN Scholar Dr. Glenn-Milo Santos and @UCSF @SF_DPH colleagues report that among sexual and gender minority individuals with mild-moderate alcohol use disorder, oral naltrexone treatment significantly reduced heavy drinking. https://t.co/bAA6PKf54Q
New NNT→Targeted Oral Naltrexone for Mild to Moderate Alcohol Use Disorder Among Sexual and Gender Minority Men: A Randomized Trial https://t.co/v9n0dUvMsU
RCT: Naltrexone was associated with a ↓ of binge-drinking days in sexual and gender minority men with AUD (IRR=0.74; 0.56-0.98; NNT=2), weeks with any binge drinking (0.83; 0.72-0.96; 7), No. of drinks/month (0.69; 0.52-0.91; 6 for 10 drinks), and craving https://t.co/9H96U787So
Professor Glenn-Milo Santos & colleagues from @SF_DPH issue new report demonstrating the effectiveness of oral naltrexone treatment to reduce heavy drinking during periods of alcohol craving. Find out more: https://t.co/EZnxA7lkwv https://t.co/1YKXepLmFF
Dr. Glenn-Milo Santos and @UCSF @SF_DPH colleagues report that among sexual and gender minority individuals with mild - moderate alcohol use disorder, oral naltrexone treatment targeting periods of alcohol craving significantly reduced heavy drinking. https://t.co/Skc6FrGBYh https://t.co/U4mEVuFa7Y
Targeted Oral Naltrexone for Mild to Moderate Alcohol Use Disorder Among Sexual and Gender Minority Men: A Randomized Trial https://t.co/5HuvvMfQqm #PubMed #Transgender